News
GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...
New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of ...
Researchers shed light on the "dark matter" of the gut, revealing a species of fungus that could potentially help counter ...
Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash ...
With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...
GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...
GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.
From my colleague Jason Mast: The first ever patient has been treated with prime editing, a powerful technology for making ...
GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.
GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results